New immune therapy combo aims to keep myeloma in check

NCT ID NCT06353022

Ongoing Disease control Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether using teclistamab or talquetamab (immune cell redirectors) after initial treatment can improve outcomes for newly diagnosed multiple myeloma. 103 patients receive either teclistamab with lenalidomide or teclistamab with talquetamab, depending on their minimal residual disease (MRD) status. The goal is to achieve and maintain MRD negativity, which indicates very low levels of cancer cells.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Teclistamab and talquetamab (immune cell redirectors) with lenalidomide
What this could lead to: If successful, this could lead to a more personalized maintenance strategy that improves long-term control of multiple myeloma and reduces the chance of relapse.
What could go wrong: This is a phase 2 trial with only 103 participants, so results may not apply to all patients. The treatments can cause serious side effects like infections and immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

APHP Hôpital La Pitié Salpétrière

Paris, 75013, France
APHP Hôpital Saint-Antoine

Paris, 75012, France
CH Lyon Sud

Lyon, 69495, France
CH de la Côte Basque

Bayonne, 64109, France
CHRU DIjon

Dijon, 21000, France
CHRU LILLE - Hôpital Claude Huriez

Lille, 59037, France
CHRU Nancy - Hôpitaux de Brabois

Vandœuvre-lès-Nancy, 54511, France
CHRU Rennes - Hôpital de Pontchaillou

Rennes, 35033, France
CHU BORDEAUX - Hôpital du Haut Lévêque

Pessac, 33604, France
CHU Caen

Caen, 14033, France
CHU Limoges

Limoges, 87000, France
CHU Montpellier

Montpellier, 34295, France
CHU Poitiers

Poitiers, 86000, France
CHU Toulouse

Toulouse, 31059, France
CHU Tours Hôpital Bretonneau

Tours, 37044, France
CHU de Nantes

Nantes, 44093, France
CHU de Strasbourg (HUS)

Strasbourg, 67200, France
Chd Vendee

La Roche-sur-Yon, 85925, France
IPC Marseille Institut Paoli Calmettes

Marseille, 13009, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.